• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • scFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Service
  • CAR Cell In Vitro Assay Service
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trials
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Analysis
  • TCR Clinical Applications
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-stop CAR-NKT Therapy Development
  • One-stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering Service
  • NK Cell Expansion Service
• One-stop Cytokine Release Syndrome (CRS) Management Solutions
• One-Stop CAR-B Therapy Development
• TCR-Like Antibody Development Service
  • MHC/Peptide Complex Production for TCR-Like Antibody Discovery
  • TCR-Like Antibody Discovery Strategies
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction and Evaluation Service
• γδ T Cells Engineering Services
• One-Stop Canine CAR-T Therapy Development Services
  • Canine CAR-T Engineering Service
  • Canine CAR-T Development Service for Hematologic Malignancies
  • Canine CAR-T Development Service for Solid Tumor
  • Canine CAR-T Cell Characterization Service
• CellRapeutics™ In Vivo Cell Engineering Development Services
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• scFv-TCR T Cell Therapy Development Service
• One-Stop Silence™ CAR-T Cell Therapy Development Services
• One-Stop mRNA CAR-T Therapy Development
• Vaccine Boosting CAR-T Cell Therapy Solutions Against Solid Tumors
  • Peptide-DC Vaccine Boosting pMHC-directed CAR-T Cell Solutions
  • Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions
  • RNA Vaccine Boosting CAR-T Cell Solutions
  • Virus-based Vaccine Boosting CAR-T Cell Solutions
• CellRapeutics™ STAb-T Cell Therapy Development
• CellRapeutics™ CART Therapy Development Services in the Non-Cancer Field
  • CellRapeutics™ CART Development Service for Autoimmune Diseases
  • CellRapeutics™ CART Development Service Powering Anti-Aging Field
  • CellRapeutics™ CART Development Service for Fibrotic Diseases
  • CellRapeutics™ CART Development Service Targeting Infectious Diseases
• One-Stop Allogeneic Cell Therapy Development Services
  • Allogeneic CAR-T Therapy Development Services
  • Allogeneic TCR-T Therapy Development Services
  • Allogeneic CAR-NK Therapy Development Services
  • Allogeneic CAR/TCR Cell Design and Engineering Services
  • Other Allogeneic Cell Therapy Development Services
• CellRapeutics™ Anti-HIV CAR Cell Therapy Development
  • HIV CAR Design and Construction
  • HIV CAR Cell Design and Engineering
• CellRapeutics™ Antibody-TCR (AbTCR) Technology
• Organoid-induced Differentiation of Conventional T Cells from hPSCs
• Modular CAR-T Cell Generation with AAV-Cpf1
• High-throughput Screening for T Cell Activity Modulator Discovery
• Nanoparticle Tiny Tech for Programming T Cells
• TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology
  • NR4A Knock Out CAR-T Cell Development with CRISPR Technology
• Virus Specific T Cell (VST) Technology
• Antibody-Coupled T Cell Receptor (ACTR) Platform
• CellRapeutics™ TCR/CAR/Antigen-Engineered Regulatory T Cells (Tregs)
  • CellRapeutics™ CAR-Treg Development
• CellRapeutics™ Chimeric Engulfment Receptor (CER) Technology
• Dendritic Vaccine Development
  • Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells
• Bispecific TCR Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
• One-Stop CAR-Monocyte Therapy Development
• Other Services
  • HLA Typing Service
  • KIR Typing Service
  • HLA Testing
  • Tumor-infiltrating Lymphocytes-based Antibody Discovery Service
  • Dog DLA Genotyping Service
  • Guinea Pig GPLA Genotyping Service
  • Mouse H2 Genotyping Service
  • Rabbit RLA Genotyping Service
  • Rat RT1 Genotyping Service
  • Rhesus Macaque MHC Genotyping Service

CART-mRNA Development Service for Cardiac Fibrosis

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Cardiac Fibrosis

Cardiac fibrosis is a condition characterized by an excessive accumulation of extracellular matrix proteins in the heart tissue. It can lead to stiffening of the heart, impaired contraction and relaxation, and eventually heart failure. It is associated with numerous heart diseases, such as heart failure, ischemic heart disease, and hypertension. Recently, chimeric antigen receptor T-cell (CAR-T) therapy has attracted attention in fibrosis research as a promising treatment for cardiac fibrosis. Scientists are currently investigating the potential for CAR-T cells to target the specific proteins in the fibrotic process. At Creative Biolabs, we are committed to designing CAR-T cells to recognize cardiac fibroblasts that are overproducing extracellular matrix proteins.

Fibroblast Activation Protein (FAP): A Target of Cardiac Fibrosis

Fibroblast Activation Protein (FAP), a serine protease, plays an important role in tissue remodeling and has a key role in the differentiation of fibroblasts to myofibroblasts. FAP is significantly upregulated in the heart during cardiac fibrosis. Increasing evidence indicates that FAP is implicated in the process of cardiac fibrosis. Therefore, FAP is a potential therapeutic target for controlling or treating cardiac fibrosis. CAR-T therapy targeting FAP could be an effective strategy to treat cardiac fibrosis.

Fig.1 Treatment of cardiac fibrosis using FAP CAR-T cells.¹

CAR-T Therapy for Cardiac Fibrosis

CAR-T therapy is a relatively new idea in the treatment of cardiac fibrosis. Scientists at Creative Biolabs are dedicated to developing the potential of CAR-T therapy in treating cardiac fibrosis. Our development service for cardiac fibrosis includes a range of processes, starting from the identification of relevant antigen targets and CAR design and construction to in vitro and in vivo testing. Once the CAR-T cells have been developed and expanded, we then analyze their functionality using cytotoxicity assays, cytokine release assays, proliferation tests, etc.

At Creative Biolabs, we offer a comprehensive CAR-T mRNA development service. Our experts are experienced in the design and construction of CAR that specifically targets proteins expressed in cardiac fibroblasts. The synthesized CAR mRNA can be the packaging of the CAR into lipid nanoparticles (LNPs).

Our wide range of customized services includes the designing of a specific CAR, synthesis of in vitro transcribed (IVT) mRNA, the encapsulation of the CAR into LNPs, and finally the validation and testing for the efficacy of the CAR-LNP construct. Our service offers a quick, reliable, and cost-effective way for your CAR-T cell therapy development.

Advantages of Our CAR mRNA & LNP Service

• The one-stop CAR mRNA & LNP platform covers comprehensive services ranging from the design and manufacture of the mRNA and CAR-LNP to the formulation and testing of the final product.
• Our trained staff are experts in the fields of genetic engineering, immunology, and oncology.
• Strict quality controls ensure the safety and effectiveness of our products.

Reference

1. Rurik, et al.; "CAR T cells produced in vivo to treat cardiac injury." Science 375.6576 (2022): 91-96.